Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), the U.S. partner of Huadong Medicine Co., Ltd. (SHE: 000963), announced today that...
BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that the U.S. Food...
ReviR Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan...
Everest Medicines Limited (HKG: 1952) announced today that the first patient has been successfully dosed...
Boehringer Ingelheim (BI) announced today the official start‑up of its local manufacturing plan for the diabetes...
Amoytop Biotech Co. Ltd. (SHA: 688278) announced today that the National Medical Products Administration (NMPA)...
Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a wholly‑owned subsidiary of China‑listed Sino Biopharmaceutical Ltd....
Everest Medicines Limited (HKG: 1952) announced today that the National Medical Products Administration (NMPA) has...
China‑listed Sichuan Kelun‑Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced today that the National Medical Products...
China‑based Zhuhai Beihai Biotech Co., Ltd. announced today that its Category 1 innovative drug BH1621 has...
Boehringer Ingelheim (BI) announced today that the U.S. Food and Drug Administration (FDA) has approved...
The National Medical Products Administration (NMPA) announced that Jiangxi Hemei Pharmaceutical Co., Ltd. has received...
The Chinese State Council has issued the Regulations on the Administration of Clinical Research and...
Bristol-Myers Squibb (BMS, NYSE: BMY) announced today that it will acquire Orbital Therapeutics (“Orbital”), a...
PegBio Co., Ltd. (HKG: 2565) announced today that it has entered into a non‑binding term...
The National Drug Alliance Procurement Office announced a schedule change for the 11th round of...
China‑based Shenyang Xingqi Pharmaceutical Co., Ltd. (SHE: 300573) announced today that the China National Medical...
Shanghai Henlius Biotech Inc. (HKG: 2696) today announced that its phase 3, randomized, double‑blind, multi‑center study...
JW (Cayman) Therapeutics Co. Ltd (HKG: 2126) announced today that the National Medical Products Administration...
Beijing Luzhu Biotechnology Co., Ltd. (HKG: 2480) announced today that its Phase 1 clinical trial of...